Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504994 | 0.88 | KLK7 (0.47) | JAK2JAK1GPR119STSKLK7 | |
| SCHEMBL15359027 | 0.87 | GPR119 (0.52) | JAK2JAK1GPR119USP30 | |
| SCHEMBL21344401 | 0.85 | GPR119 (0.52) | JAK2JAK1GPR119 | |
| SCHEMBL11538529 | 0.85 | L3MBTL1 (0.49) | GAASMN1; SMN2 | |
| SCHEMBL15359029 | 0.83 | GPR119 (0.47) | GPR119USP30THRB | |
| SCHEMBL4739542 | 0.82 | PARP1 (0.45) | JAK2JAK1GPR119STSUSP30 | |
| SCHEMBL21605818 | 0.82 | GPR119 (0.42) | JAK2JAK1GPR119USP30KDM4E | |
| SCHEMBL15352654 | 0.82 | TACR3 (0.43) | KDM4EPKMGAA | |
| SCHEMBL9052963 | 0.82 | TACR3 (0.43) | KDM4EPKMGAA | |
| SCHEMBL2451668 | 0.81 | GPR119 (0.50) | JAK2JAK1GPR119STSUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179671-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8557839-B2 | Fused ring azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120225856-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-1735308-B1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070281928-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS INCORPORATED | 2007-12-06 | — | — | US | disclosed |
| EP-0869968-B1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1735308-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6313140-B1 | ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6110932-A | INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | JAK2 857/4885JAK1 2092/4885GPR119 218/4885 |
| US-20140179671-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A2 | JAK2 4383/4885JAK1 4400/4885GPR119 174/4885 |
| US-20120225856-A1 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A2 | JAK2 4383/4885JAK1 4400/4885GPR119 174/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | JAK2 2647/4885JAK1 3590/4885GPR119 60/4885 |
| US-20070281928-A1 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators | NR3C1, NR3C2, NR5A2 | JAK2 4383/4885JAK1 4400/4885GPR119 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.